---
title: "Strategies for reopening in the forthcoming COVID-19 era in China"
date: 2022-05-09
tags: 转载 COVID19
categories: article
---

作者：Wei-jie Guan, Nan-shan Zhong

出处：https://academic.oup.com/nsr/article/9/3/nwac054/6564385

版权：本作品采用「[Attribution 4.0 International (CC BY 4.0)](https://creativecommons.org/licenses/by/4.0/)」许可协议进行许可。

# Strategies for reopening in the forthcoming COVID-19 era in China

Wei-jie Guan, Nan-shan Zhong

_National Science Review_, Volume 9, Issue 3, March 2022, nwac054, https://doi.org/10.1093/nsr/nwac054

Published: 06 April 2022

The transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the culprit pathogen of coronavirus disease 2019 (COVID-19), has resulted in more than 0.43 billion cases and 6 million deaths globally. Compared with other existing variants of concern, the Omicron variant is characterized by significantly greater infectivity (Ro ≈ 6), greater tropism of the upper respiratory tract and lower severity of human infections [1]. These characteristics of the Omicron variant are the basis upon which several developed countries are considering reopening.

Different policies have been adopted worldwide during the COVID-19 era. The community-based dynamic zeroing policy has played a pivotal role in minimizing the number of laboratory-confirmed cases and deaths in mainland China. The rapid roll-out of vaccinations, as well as herd immunity, have formed the fundamentals of the ‘total opening’ of some developed countries. This, however, does not necessarily justify rapid and total opening in mainland China. Omicron confers a considerably higher mortality risk than seasonal influenza, and would likely result in social instability and the emergence of other novel variants with a greater infectivity.

The dynamic zeroing policy has been adopted for maintaining effective disease prevention and control. However, China needs to reopen so as to normalize socio-economic development and adapt to global reopening. Prolonged dynamic zeroing cannot be pursued in the long run. There are several recommendations on how China could reopen in an orderly and effective manner.

First, enforcing nationwide vaccination is crucial to safeguarding herd immunity. As of 28 February 2022, China has vaccinated 87.64% of the whole population with at least two doses of SARS-CoV-2 vaccines, with 40.32% completing the third-dose boosting vaccination. However, the vaccination rate was still markedly lower than 83% in the Chinese population aged >70 years in mainland China and even lower in Hong Kong [2]. The full dose vaccination among over 80% of the population was associated with a markedly reduced mortality rate [2]. Homologous boosting with a third dose of BioNTech vaccine significantly increased the neutralizing antibody titers against the Omicron variant [3]. Two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac, Sinovac Biotech) conferred protection against the Delta variant [4], and an analysis of the protective effects of the third dose of homologous CoronaVac vaccines on the Omicron variant is underway. Furthermore, recent laboratory data have demonstrated that heterologous boosting of the two-dose CoronaVac vaccine with either the BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine, the recombinant protein subunit vaccine (ZF2001, Zhifei Longcom Biopharmaceutical) [5] or the adenovirus vaccine (CanSino Biologics) could markedly enhance protection against the Omicron variant. These findings have lent support to the heterologous boosting strategy intended to increase the rate of protection against variants of concern (particularly the Omicron variant).

Second, efforts to reduce the risk of progression to critical illness and death would benefit from the acceleration of research and development of targeted medications and potent neutralizing antibodies. In addition to paxlovid and molnupiravir, the therapeutic effects of medications (e.g. VV116) and neutralizing antibodies (BRII-196 and BRII-198) have provided hope with regard to improving clinical outcomes, although conducting phase three studies within mainland China would be challenging due to limited patient sources. International collaboration should therefore be encouraged.

Third, rapid antigen testing should be prioritized in community settings. Antigen testing has been associated with significantly shorter turnaround times and less reliance on medical facilities and personnel compared to nucleic acid testing. This ensures timely identification of the source patient, on which basis population-based screening with viral nucleic acid testing can be reserved for close contacts (particularly the imported cases).

Fourth, we should strengthen longitudinal follow-up investigations of infected cases during the latency and convalescent periods. In-depth analysis of the infectivity of imported cases (including those showing re-positive test results) would inform the policy maker with regard to the minimal duration of quarantine and the management of re-positive cases after hospital discharge.

Finally, performing pilot investigations in certain designated cities or regions, as well as adjusting the policy according to the epidemic characteristics of imported cases, will be equally vital for verifying the outcomes of the transition towards safe and orderly social reopening in China.

## Acknowledgements

We thank Kai-ping Li for her help with the material for this editorial.

## REFERENCES

1.Our World in Data. Coronavirus (COVID-19) Cases. https://ourworldindata.org/covid-cases#confirmed-cases (7 March 2022, date last accessed).

2.Medical Observations. Why Can’t Hong Kong “Co-Exist with SARS-CoV-2” as with Singapore? https://www.shangyexinzhi.com/article/4638096.html (7 March 2022, date last accessed).

3.Pérez-Then E , Lucas C, Cochon L et al. Nat Med 2022; 28: 481–5.[10.1038/s41591-022-01705-6](https://doi.org/10.1038/s41591-022-01705-6) [Crossref](http://dx.doi.org/10.1038/s41591-022-01705-6) [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35051990)

4.Li XN, Huang Y, Jing QL et al. Emerg Microbes Infect 2021; 10: 1751–9 [10.1080/22221751.2021.1969291](https://doi.org/10.1080/22221751.2021.1969291) [Crossref](http://dx.doi.org/10.1080/22221751.2021.1969291) [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34396940)

5.Ai J, Zhang H, Zhang Q et al. Cell Res 2022; 32: 103–6.[10.1038/s41422-021-00590-x](https://doi.org/10.1038/s41422-021-00590-x) [Crossref](http://dx.doi.org/10.1038/s41422-021-00590-x) [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34815511)

© The Author(s) 2022. Published by Oxford University Press on behalf of China Science Publishing & Media Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

## Supplementary data

nwac054_Supplemental_File - doc file

## 简单主体内容翻译

翻译：Bing Translate 校译：没有

### 中国即将到来的新冠肺炎疫情时代的重新开放策略

关伟杰，钟南山

国家科学评论，第 9 卷，第 3 期，2022 年 3 月，nwac054，https://doi.org/10.1093/nsr/nwac054

出版日期：2022-04-06

严重急性呼吸综合征冠状病毒-2（SARS-CoV-2）是 2019 年冠状病毒病（COVID-19）的罪魁祸首病原体，其传播已导致全球超过 4.3 亿例病例和 600 万人死亡。与其他现有的关注变异相比，Omicron 变异体的特征在于显著增加感染性（Ro ≈6）、上呼吸道向性更大以及人类感染的严重程度较低。Omicron 变体的这些特征是几个发达国家考虑重新开放的基础。

在 COVID-19 时代，全球采取了不同的政策。基于社区的动态归零政策在最大限度地减少中国大陆实验室确诊病例和死亡人数方面发挥了关键作用。疫苗接种的迅速普及以及群体免疫力构成了一些发达国家“全面开放”的基础。然而，这并不一定证明中国大陆迅速和全面开放是合理的。Omicron 赋予季节性流感的死亡率风险要高得多，并且可能导致社会不稳定和出现具有更大传染性的其他新型变体。

为保持有效的疾病防控，采取了动态归零政策。然而，中国需要重新开放，以实现社会经济发展正常化并适应全球重新开放。从长远来看，无法实现长时间的动态归零。关于中国如何以有序和有效的方式重新开放，有几项建议。

首先，在全国范围内实施疫苗接种对于保障群体免疫至关重要。截至 2022 年 2 月 28 日，中国已为 87.64%的人口接种了至少两剂 SARS-CoV-2 疫苗，其中 40.32%完成了第三剂加强疫苗接种。然而，在中国大陆年，>70 岁的中国人口的疫苗接种率仍明显低于 83%，在香港甚至更低。在 80%以上的人群中接种全剂量疫苗与死亡率显著降低相关。使用第三剂 BioNTech 疫苗进行同源增强可显着增加针对 Omicron 变体的中和抗体滴度。两剂灭活的 SARS-CoV-2 疫苗（CoronaVac，Sinovac Biotech）提供了对 Delta 变体的保护，并且正在分析第三剂同源 CoronaVac 疫苗对 Omicron 变体的保护作用。此外，最近的实验室数据表明，使用 BNT162b2（Comirnaty，Pfizer-BioNTech）疫苗，重组蛋白亚基疫苗（ZF2001，智飞龙科生物制药）或腺病毒疫苗（CanSino Biologics）异源增强可以显着增强对 Omicron 变体的保护。这些发现为异源增强策略提供了支持，该策略旨在提高对关注变体（特别是 Omicron 变体）的保护率。

其次，努力降低进展为危重疾病和死亡的风险将受益于加速研究和开发靶向药物和强效中和抗体。除了帕洛维和莫努匹拉韦外，药物（例如 VV116）和中和抗体（BRII-196 和 BRII-198）的治疗效果为改善临床结果提供了希望，尽管由于患者来源有限，在中国大陆内进行三期研究将具有挑战性。因此，应鼓励国际合作。

第三，在社区环境中应优先考虑快速抗原检测。与核酸检测相比，抗原检测的周转时间显著缩短，对医疗设施和人员的依赖程度更低。这确保了及时确定来源患者，在此基础上，可以保留对密切接触者（特别是输入病例）进行基于人群的病毒核酸检测筛查。

四是加强潜伏期、恢复期感染病例纵向随访调查。对输入性病例（包括检测结果为再阳性的病例）的传染性进行深入分析，将为政策制定者提供关于隔离的最短时间和出院后对再阳性病例的管理的信息。

最后，在某些指定城市或地区开展试点调查，并根据输入性病例的流行特征调整政策，对于验证中国向安全有序社会开放过渡的结果同样重要。

我们感谢李开平为这篇社论提供材料。
